Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells

Chiara M. Mazzanti, Anita Tandle, Dominique Lorang, Nick Costouros, David Roberts, Generoso Bevilacqua, Steven K. Libutti

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

A tumor needs to initiate angiogenesis in order to develop its own blood supply, to grow, to invade, and to spread. Angiogenesis, under normal conditions, is a tightly regulated balance between endogenous pro- and antiangiogenic factors. In this study, we investigated, by microarray analysis, the effects of two known antiangiogenic agents (endostatin and fumagillin) on the gene expression profiles of human umbilical vein endothelial cells (HUVEC) in order to elucidate pathways common to the effects of these agents. We observed a majority of gene expression changes within 1 and 2 h of treatment. The genes demonstrating these early expression changes are involved in cell proliferation, gene transcription, and a number have unknown functions. We selected four genes (DOC1, KLF4, TC-I, IDI) from the microarray profile that showed a similar pattern of expression for both of the antiangiogenic agents we tested. We then used small interfering RNAs (siRNA) in an attempt to better understand the role of these selected genes in the inhibitory activity of these agents. Because the gene expression changes occurred within 1 and 2 h of treatment, these genes might be involved in the initial pathways of angiogenesis inhibition.

Original languageEnglish (US)
Pages (from-to)1585-1593
Number of pages9
JournalGenome Research
Volume14
Issue number8
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Endostatins
Endothelial Cells
Angiogenesis Inhibitors
Genes
Gene Expression
Human Umbilical Vein Endothelial Cells
Microarray Analysis
Transcriptome
Small Interfering RNA
Cell Proliferation
fumagillin
Neoplasms

ASJC Scopus subject areas

  • Genetics

Cite this

Mazzanti, C. M., Tandle, A., Lorang, D., Costouros, N., Roberts, D., Bevilacqua, G., & Libutti, S. K. (2004). Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells. Genome Research, 14(8), 1585-1593. https://doi.org/10.1101/gr.2552804

Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells. / Mazzanti, Chiara M.; Tandle, Anita; Lorang, Dominique; Costouros, Nick; Roberts, David; Bevilacqua, Generoso; Libutti, Steven K.

In: Genome Research, Vol. 14, No. 8, 08.2004, p. 1585-1593.

Research output: Contribution to journalArticle

Mazzanti, CM, Tandle, A, Lorang, D, Costouros, N, Roberts, D, Bevilacqua, G & Libutti, SK 2004, 'Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells', Genome Research, vol. 14, no. 8, pp. 1585-1593. https://doi.org/10.1101/gr.2552804
Mazzanti, Chiara M. ; Tandle, Anita ; Lorang, Dominique ; Costouros, Nick ; Roberts, David ; Bevilacqua, Generoso ; Libutti, Steven K. / Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells. In: Genome Research. 2004 ; Vol. 14, No. 8. pp. 1585-1593.
@article{32bc283d1d74419aa3567fb258e964c2,
title = "Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells",
abstract = "A tumor needs to initiate angiogenesis in order to develop its own blood supply, to grow, to invade, and to spread. Angiogenesis, under normal conditions, is a tightly regulated balance between endogenous pro- and antiangiogenic factors. In this study, we investigated, by microarray analysis, the effects of two known antiangiogenic agents (endostatin and fumagillin) on the gene expression profiles of human umbilical vein endothelial cells (HUVEC) in order to elucidate pathways common to the effects of these agents. We observed a majority of gene expression changes within 1 and 2 h of treatment. The genes demonstrating these early expression changes are involved in cell proliferation, gene transcription, and a number have unknown functions. We selected four genes (DOC1, KLF4, TC-I, IDI) from the microarray profile that showed a similar pattern of expression for both of the antiangiogenic agents we tested. We then used small interfering RNAs (siRNA) in an attempt to better understand the role of these selected genes in the inhibitory activity of these agents. Because the gene expression changes occurred within 1 and 2 h of treatment, these genes might be involved in the initial pathways of angiogenesis inhibition.",
author = "Mazzanti, {Chiara M.} and Anita Tandle and Dominique Lorang and Nick Costouros and David Roberts and Generoso Bevilacqua and Libutti, {Steven K.}",
year = "2004",
month = "8",
doi = "10.1101/gr.2552804",
language = "English (US)",
volume = "14",
pages = "1585--1593",
journal = "Genome Research",
issn = "1088-9051",
publisher = "Cold Spring Harbor Laboratory Press",
number = "8",

}

TY - JOUR

T1 - Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells

AU - Mazzanti, Chiara M.

AU - Tandle, Anita

AU - Lorang, Dominique

AU - Costouros, Nick

AU - Roberts, David

AU - Bevilacqua, Generoso

AU - Libutti, Steven K.

PY - 2004/8

Y1 - 2004/8

N2 - A tumor needs to initiate angiogenesis in order to develop its own blood supply, to grow, to invade, and to spread. Angiogenesis, under normal conditions, is a tightly regulated balance between endogenous pro- and antiangiogenic factors. In this study, we investigated, by microarray analysis, the effects of two known antiangiogenic agents (endostatin and fumagillin) on the gene expression profiles of human umbilical vein endothelial cells (HUVEC) in order to elucidate pathways common to the effects of these agents. We observed a majority of gene expression changes within 1 and 2 h of treatment. The genes demonstrating these early expression changes are involved in cell proliferation, gene transcription, and a number have unknown functions. We selected four genes (DOC1, KLF4, TC-I, IDI) from the microarray profile that showed a similar pattern of expression for both of the antiangiogenic agents we tested. We then used small interfering RNAs (siRNA) in an attempt to better understand the role of these selected genes in the inhibitory activity of these agents. Because the gene expression changes occurred within 1 and 2 h of treatment, these genes might be involved in the initial pathways of angiogenesis inhibition.

AB - A tumor needs to initiate angiogenesis in order to develop its own blood supply, to grow, to invade, and to spread. Angiogenesis, under normal conditions, is a tightly regulated balance between endogenous pro- and antiangiogenic factors. In this study, we investigated, by microarray analysis, the effects of two known antiangiogenic agents (endostatin and fumagillin) on the gene expression profiles of human umbilical vein endothelial cells (HUVEC) in order to elucidate pathways common to the effects of these agents. We observed a majority of gene expression changes within 1 and 2 h of treatment. The genes demonstrating these early expression changes are involved in cell proliferation, gene transcription, and a number have unknown functions. We selected four genes (DOC1, KLF4, TC-I, IDI) from the microarray profile that showed a similar pattern of expression for both of the antiangiogenic agents we tested. We then used small interfering RNAs (siRNA) in an attempt to better understand the role of these selected genes in the inhibitory activity of these agents. Because the gene expression changes occurred within 1 and 2 h of treatment, these genes might be involved in the initial pathways of angiogenesis inhibition.

UR - http://www.scopus.com/inward/record.url?scp=4444284023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444284023&partnerID=8YFLogxK

U2 - 10.1101/gr.2552804

DO - 10.1101/gr.2552804

M3 - Article

C2 - 15289477

AN - SCOPUS:4444284023

VL - 14

SP - 1585

EP - 1593

JO - Genome Research

JF - Genome Research

SN - 1088-9051

IS - 8

ER -